Afternoon Symposium - Gamete Reserve I - Testis

Date:October 21, 2014

Time:4:15 pm - 6:15 pm

Location:HCC313 - Hawaii Convention Center


Stefan Schlatt, Ph.D. (Chair), Institute of Reproductive Medicine and Andrology, University of Münster

Daniel H. Williams, M.D., University of Wisconsin

Cigden Tanrikut, M.D., Massachusetts General Hospital

Richard J. Chaillet, M.D., Ph.D., University of Pittsburgh


Supported by an educational grant from Ferring Pharmaceuticals, Inc.

Needs Assessment and Description
Fertility preservation in the male is routinely performed by cryopreservation of sperm. However, prepubertal or azoospermic patients do not have this option. In recent years many scientific breakthroughs were achieved, creating novel options for male fertility preservation based primarily on the existence of spermatogonial stem cells. Testicular stem cells can be cryopreserved from birth onward, and strategies to create sperm by transplantation of the stem cell back to the testis, auto- or xenografting, or in vitro spermatogenesis may provide exciting novel clinical treatment options. Many centers have therefore started to create banks of cryopreserved immature testis tissue. This translational symposium deals with several relevant aspects of the introduction of intracytoplasmic sperm injection (ICSI) on fertility preservation in male patients, causes of infertility in oncological patients or men with Klinefelter syndrome, and the role of genetic or epigenetic patterns in germ cells. Preclinical perspectives for male fertility preservation will be presented. In addition to reproductive scientists, the symposium is highly relevant for a wide range of clinicians who are needed to perform these procedures in a clinical setting, including (pediatric) endocrinologists and oncologists, urologists, andrologists, and other assisted reproductive technology (ART) providers. 

Learning Objectives
At the conclusion of this session, participants should be able to: 

  1. Describe the devastating effects of genetic changes or exposure to cytotoxic treatments on male germline stem cells leading to male infertility. 
  2. Identify the options provided by modern ART procedures (cryopreservation, ICSI) for male fertility preservation, and potential risks for genetic or epigenetic changes in sperm. 
  3. Estimate the potential of spermatogonial stem cells as target cells for generation of sperm via transplantation, grafting, or in vitro culture. 

ACGME Competency
Medical Knowledge 

Future treatment for fertility preservation in prepubertal boys undergoing oncological treatment may be performed by:
a. Combined treatment with LH and FSH to induce stimulation of spermatogenesis after cancer therapy.
b. Bioptic retrieval and cryopreservation of immature testicular tissue and subsequent generation of sperm from cryopreserved stem cells by transplantation, grafting, or in vitro culture.
c. Suppression of spermatogonial stem cell turnover via down-regulation of the gonadotropic hormones through treatment with GnRH antagonists.
d. Cryopreservation of sperm obtained by electroejaculation.


View Details
Learn More | Join | Renew
Back to Top